← Back to Search

Tyrosine Kinase Inhibitor

Serial Ultrasound for Kidney Cancer

N/A
Waitlist Available
Led By Alice C Fan, MD
Research Sponsored by Stanford University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Pathology-confirmed diagnosis of metastatic RCC
18 years of age or older
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Awards & highlights

Summary

This trial will look at whether changes in how blood flows through tumors after 3 weeks of treatment can predict whether the treatment is working at 12 weeks.

Who is the study for?
This trial is for adults with metastatic renal cell carcinoma (advanced kidney cancer) who are about to start treatment. They must have a tumor larger than 1 cm that can be seen on ultrasound and agree to the study's procedures. People with health issues that could interfere with their participation, as judged by the medical team, cannot join.
What is being tested?
The study tests if early changes in blood flow within tumors, measured by power doppler ultrasound after starting treatment, can predict how well patients will respond at 12 weeks. It compares two groups: one receiving VEGFR2 inhibitors plus immune therapy and another getting non-immune therapies.
What are the potential side effects?
Possible side effects from VEGFR2 inhibitors include high blood pressure, fatigue, diarrhea, mouth sores, hand-foot syndrome (redness and pain in hands/feet), and increased risk of bleeding or clotting events.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My kidney cancer has spread to other parts of my body.
Select...
I am 18 years old or older.
Select...
I am planned to be treated with a specific drug combination for my condition.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Measure Initial Objective response
Secondary study objectives
Lesion response compared to baseline
Progression free survival (PFS)
Relative change in tumor burden compared to baseline

Trial Design

2Treatment groups
Experimental Treatment
Group I: Tyrosine kinase (TKI) inhibitor plus immune checkpoint inhibitor (ICI)Experimental Treatment3 Interventions
Patients are planned to be treated with vascular endothelial growth factor 2 (VEGFR2) tyrosine kinase inhibitor (TKI) plus immune checkpoint inhibitor (ICI)
Group II: Non-ICI therapyExperimental Treatment2 Interventions
Patients are planned to be treated with non-ICI therapy
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Doppler Ultrasound
2019
N/A
~250

Find a Location

Who is running the clinical trial?

National Institutes of Health (NIH)NIH
2,765 Previous Clinical Trials
8,133,489 Total Patients Enrolled
Stanford UniversityLead Sponsor
2,448 Previous Clinical Trials
17,492,372 Total Patients Enrolled
Alice C Fan, MDPrincipal InvestigatorStanford University

Media Library

Vascular Endothelial Growth Factor Receptor 2 tyrosine kinase inhibitor (Tyrosine Kinase Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT04508725 — N/A
Kidney Cancer Research Study Groups: Non-ICI therapy, Tyrosine kinase (TKI) inhibitor plus immune checkpoint inhibitor (ICI)
Kidney Cancer Clinical Trial 2023: Vascular Endothelial Growth Factor Receptor 2 tyrosine kinase inhibitor Highlights & Side Effects. Trial Name: NCT04508725 — N/A
Vascular Endothelial Growth Factor Receptor 2 tyrosine kinase inhibitor (Tyrosine Kinase Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04508725 — N/A
~5 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top